INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest to Present at the Piper Jaffray 28th Annual Health Care Conference
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 28, 2016-- NantKwest Inc. (Nasdaq:NK) today announced that Company management will present at the Piper Jaffray 28 th Annual Health Care Conference in New York, NY at 4:00 pm Eastern Time (ET) on Tuesday, November 29, 2016 .
View HTML
Toggle Summary NantKwest to Present at Upcoming Investment and Healthcare Conferences
CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 13, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell-based therapeutics company, today announced that the company will be presenting and conducting one-on-one meetings at a number of investment and healthcare conferences in the
View HTML
Toggle Summary NantKwest to Present at Upcoming Investment and Healthcare Conferences
CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 13, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell-based therapeutics company, today announced that the company will be presenting and conducting one-on-one meetings at a number of investment and healthcare conferences in the
View HTML
Toggle Summary NantKwest to Present at Upcoming Investment Conferences
CULVER CITY, CALIFORNIA-(BUSINESS WIRE), September 5, 2017 NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at three investment conference in September.
View HTML
Toggle Summary NantKwest to Present at Upcoming Investor Conferences
CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 6, 2017-- NantKwest (Nasdaq:NK) today announced that members of the company’s management team will be presenting at the following upcoming investor conferences: Cowen & Company’s 37th Annual Healthcare Conference on Wednesday, March 8th , at 9:20am ET
View HTML
Toggle Summary NantKwest to Present at Upcoming Science & Medicine Conferences
CULVER CITY, Calif. --(BUSINESS WIRE)--Apr. 23, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at two science and medicine conferences in the months of April and May 2018 .
View HTML
Toggle Summary NantKwest to Present Data at the 58th Annual Meeting of the American Society of Hematology
Presentation of Combination Therapy with a CS1.taNK and Daratumumab in Multiple Myeloma Presentation of Activated Natural Killer Cell Therapy (aNK) in Acute Myeloid Leukemia Presentation of Preclinical Data of a CD19.taNK Targeting Non-Hodgkin Lymphoma CULVER CITY, Calif. --(BUSINESS WIRE)--Nov.
View HTML
Toggle Summary NantKwest to Present Data at the 58th Annual Meeting of the American Society of Hematology
Presentation of Combination Therapy with a CS1.taNK and Daratumumab in Multiple Myeloma Presentation of Activated Natural Killer Cell Therapy (aNK) in Acute Myeloid Leukemia Presentation of Preclinical Data of a CD19.taNK Targeting Non-Hodgkin Lymphoma Culver City, November 3, 2016 NantKwest Inc.
View HTML
Toggle Summary NantKwest to Present Data at the 59th Annual Meeting of the American Society of Hematology
Oral Presentation to Highlight Preclinical Data on a Chimeric Antigen Receptor (CAR) Engineered Natural Killer Cell Therapy (CD19.taNK) in CD Resistant B-Cell Non-Hodgkin Lymphoma CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 4, 2017-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation,
View HTML
Toggle Summary NantKwest to Present Data on the First Next Generation GMP-Grade NK Cell Line for Combination Immunotherapy with Rituximab, Trastuzumab, and Daratumumab at Upcoming AACR Cancer Conference
Positive Preclinical Data Of The First “Off The Shelf,” GMP-Grade, IL-2-Independent NK Cell Line Expressing The High-Affinity Fc-Receptor To Augment Antibody Therapeutics CULVER CITY, Calif.  –  April 15, 2016  - NantKwest Inc.
View HTML